Cellular Biotechnology Lab
@LAB_BIOC
Followers
139
Following
265
Media
46
Statuses
268
Cellular Biotechnology Lab at ISCIII Pediatric Cancer / Advanced Therapy / Immunotherapy https://t.co/kalE8dtJnL
Madrid - Spain
Joined April 2023
RT @SaludISCIII: Hoy arranca la jornada principal del Encuentro Internacional sobre Terapias Avanzadas, que celebramos en nuestro campus de….
0
7
0
Join us May 28 at ISCIII Majadahonda (Madrid, Spain) 🏨for the Workshop on Adoptive Cell Therapies — dive into the latest on CAR-T and adoptive therapies 💉🧬 . Free registration via email: workshop.nextgencar@gmail.com . Don't miss out!".
El 28 de mayo se celebra el 🔬 Workshop on Adoptive Cell Therapies en el Campus de Majadahonda del @SaludISCIII para compartir las últimas novedades en terapias celulares adoptivas y CAR-T 💉. 📧 ¡Y es totalmente gratuito! Regístrate vía email a workshop.nextgencar@gmail.com
0
0
0
RT @JavierGC280: 🔬 Workshop on Adoptive Cell Therapies! 🔬. Open scientific workshop on May 28, 2025, hosted at the Majadahonda Campus of….
0
8
0
Coming soon, see you in Madrid (Majadahonda) !!!.
🧬 3rd INTERNATIONAL WORKSHOP on ADVANCED THERAPIES– register! . 🏬 We are pleased to host this event at ISCIII, on our Majadahonda campus @SaludISCIII. 💡 Cutting-edge science. A must-attend event for professionals in cell & gene therapy manufacturing
0
0
0
In the pilot phase, no clinical responses were observed.in 18 patients unselected TILs. However, when TILs were selected for neoantigen recognition, 3 responses were seen in 39 patients (7.7%). Pembrolizumab.was added, and 8 objective responses were.seen in 34 patients (23.5%)
0
3
5
Osteosarcoma remains a highly aggressive bone malignancy with limited therapeutic options, necessitating novel treatment strategies. Minireview:.
0
0
0
Now, AstraZeneca has announced plans to acquire EsoBiotec for up to 925 M€. The deal includes an initial payment of 389 M€, with up to 526 M€ contingent on achieving specific development and regulatory milestones.
managedhealthcareexecutive.com
EsoBiotec’s platform has the potential to eliminate the complex and time-consuming process for manufacturing, helping to make CAR-T cell therapies more accessible.
0
0
0
The first patient received a single intravenous dose without prior lymphodepletion. After 28 days, their bone marrow showed no detectable cancer, and free light chain levels normalized, with no major side effects reported.
1
0
0
EsoBiotec SA has launched a clinical trial for ESO-T01, in vivo BCMA CAR-T therapy for multiple myeloma. ESO-T01 reprograms T cells directly using the ENaBL platform, which uses a viral vector said to be “immune shielded” via the removal of MHC1 and the overexpression of CD47
1
1
2
T cell receptor precision editing of regulatory T cells for.celiac disease. Authors generated gluten- reactive HLA- DQ2.5–restricted CD4+ engineered eTregs. e Tregs hold therapeutic potential for restoring gluten.tolerance in their mice model.
0
2
4
RT @JavierGC280: Hace 20 años que creamos nuestra Fundación. Hoy nos unimos a la UAM para seguir apoyando la investigación, los tratamiento….
0
1
0
Methyltransferases EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. Treated tumors showed upregulation of genes related to adhesion, B cell activation, and inflammatory responses, and increased avidity to CAR-T.
cell.com
Porazzi et al. highlight how inhibiting the epigenetic regulators EZH2 and EZH1 enhances cancer cell immunogenicity, boosting the effectiveness of CAR- and TCR-engineered T cells across liquid and...
0
3
7
RT @LAB_BIOC: Clonal expansion of CD8+ T cells is an immunological driver of bispecific T cell engagers (TCE). Naive T cells require additi….
cell.com
Bispecific T cell engagers (TCEs) have shown promise in the treatment of various cancers, but their mode of action in humans is elusive. Providing new insight into immunological mechanisms, Friedrich...
0
1
0
Clonal expansion of CD8+ T cells is an immunological driver of bispecific T cell engagers (TCE). Naive T cells require additional MHC class I signal and differentiate upon TCE activation. Exhausted CD8+ clones predicts response failure in multiple myeloma.
cell.com
Bispecific T cell engagers (TCEs) have shown promise in the treatment of various cancers, but their mode of action in humans is elusive. Providing new insight into immunological mechanisms, Friedrich...
0
1
2
Generation of allogenic CAR invariant natural killer T (CAR-NKT) cells from HSC. Anti-CD33 CAR-NKT cells exhibit strong BM homing and effectively target AML and MDS blasts. TCR-CD1d and NK receptors help in the elimination of leukemic stem cells.
nature.com
Nature Communications - Yang and colleagues have previously reported a clinically guided culture method to generate allogeneic CAR-NKT cells by engineering human hematopoietic stem and progenitor...
0
1
2
🔬Key Findings:.🔹 CAR transfer between T cells without a specific binding partner.🔹 Untransduced T cells gain antitumoral potential through trogocytosis.🔹 The transmembrane domain dictates protein exchange.🔹 CD4 T cells can respond to MHCI after acquiring TCRs from CD8.
1
0
1
CAR T cells can exchange CAR through trogocytosis! Understanding this mechanism could lead to more effective CAR T cell therapies.
science.org
Chimeric antigen receptor trogocytosis transfers antitumor immunity between T cells and is dictated by their transmembrane domain.
1
0
0